Ever been told there is a “science” to making money? Three months, 59 trading sessions, less than $50 in commissions. That’s all it took for long investors to realize a 4,139% profit, 1,047% since December 1st alone. It’s crazy, but those with the foresight to put $500 into the penny stock of Amarantus BioScience Inc. (OTC:AMBS) in October, this week it was worth $20,695. The gains have been huge and since entering into the LOI at the end of 2012 with Brewer Sports International, LLC and Toi Cook Management Group, LLC, AMBS stock could be in for a huge run throughout biotech friendly January.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
AMBS Stock Chart
Market Cap: 33.77M
Last: 0.1506 ▲ 0.0009 (0.60%)
Volume: 20,113,241
Dollar Volume: $2,850,432
Open: 0.1519
High: 0.1535
Low: 0.131
Trades: 1,379
14-Day Rel Strength: 69.87%
14-Day Stochastic: 71.35%
Looking for Hot Penny Stocks?
Click here and get Our Penny Stock Picks FREE
On September 21, 2012, after the market had closed, alerts were first issued to kick off the run AMBS stock has been on starting at $0.0051. The predictions made were more accurate and had a bigger impression than many expected. “We’re expecting this one to be a monster. Our last two Biotech’s were Huge Winners and we feel this New Sub-Penny Biotech play could be the top pick in the micro-cap market for 2012.” Check out the amazing stock chart since September 21:
AMBS has had an amazing run so far, and it is looking much like the same pattern Cannabis Science (CBIS) created at the start of 2012. The recent agreement with Brewer Sports International to collaborate in the coordination and co-hosting of an international symposium, #C4CT Concussion Awareness Conference, is set to kick off next week in San Francisco, CA at the OneMedForum and Biotech Showcase.
Amarantus’ efforts to bring attention to their proprietary therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor, MANF, is in the hot seat this week, as is AMBS stock. Bringing thought leaders in the field of Traumatic Brain Injury drug and diagnostic research & development is focused on more than just professional athletes, former professional athletes and celebrity sports figureheads that share the Company’s desire to support research into new TBI treatments.
Brain degenerative diseases that were once designated for people in their 70’s and 80’s are now showing up in 50-to-60 year-olds, sometimes even as early as the 30’s and 40’s. Compounding the problem is the medical industry’s often mistakenly missed diagnosis of the early stages of Alzheimer’s, dementia, Parkinson’s and other brain diseases as normal aging. Amarantus may or may not have the right treatment with their MANF, but by publicly discussing head injuries and their side effects, which include Parkinson’s disease, Alzheimer’s disease and other disorders in a symposium of their peers will be the make or break for new agreements or old share prices.
About AMBS Stock
Amarantus BioScience Inc., founded in January 2008, is a California-based development-stage biotechnology company focused on developing their intellectual property and proprietary technology to develop drug candidates to treat human diseases.
Last 5 Trading Sessions:
| Date | Last | Change | % Change | Volume |
| 01/04/13 | 0.1506 | +0.0009 | +0.60% | 20,113,240 |
| 01/03/13 | 0.1497 | -0.0223 | -12.97% | 39,804,402 |
| 01/02/13 | 0.1720 | +0.0400 | +30.30% | 27,318,699 |
| 12/31/12 | 0.1320 | +0.0240 | +22.22% | 12,705,200 |
| 12/28/12 | 0.1080 | +0.0325 | +43.05% | 23,817,600 |
Bottom Line: Sure the commissions killed you, $20 in and out, and the capital gains tax due in 2014 will be a burden, but when you can turn $500 into that kind of money based on picking penny stocks at the right time, I don’t care who you are — you’re foolish to not want to learn how. With how AMBS stock traded on Friday and the upcoming scheduled appearances for Amarantus BioScience, you would be equally foolish to not have it on your penny stocks to watch list for next week.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareJAN
